Such compounds include RP1 (Replimune -1), a modified herpes simplex 1, which can induce tumor regression by stimulating GALV-GP R-protein (glycoprotein of gibbon ape leukemia virus) and GM-CSF (granulocyte/macrophage colony-stimulating factor) when used alone or in combination with nivolumab. This evidence concerns the gene CSF2 and neoplasm.